M. Karolyi, E. Pawelka, S. Omid, F. Koenig, V. Kauer, B. Rumpf, . . . A. Zoufaly. (2022). Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). Frontiers Media S.A..
Chicago Style (17th ed.) CitationM. Karolyi, et al. Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). Frontiers Media S.A., 2022.
MLA (9th ed.) CitationM. Karolyi, et al. Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT). Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.